User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: A future opportunity?

Primary tabs

Tejpar, Sabine [Digestive Oncology Unit, University Hospital Gasthiusberg, Leuven, Belgium] Piessevaux, Hubert [UCL]

Treatment options for colorectal cancer have increased substantially in the past decade, with the introduction of novel biological therapies targeting cancer-specific molecules leading to significantly improved outcomes. Despite access to these treatments, we are not yet in an era where we can fully personalize treatment choices for patients with colorectal cancer. A number of prognostic and predictive markers have been identified that appear to be directly related to sensitivity to targeted therapies, such as those against epidermal growth factor receptor. However, the sensitivities of individual tumors toward different biological agents appear to be more complex. It seems that a more complete molecular signature of the tumor must be taken into account when making individual treatment choices. In the absence of having fully elucidated the influence of these prognostic or predictive markers, other surrogate markers of early treatment success may be useful in determining whether to continue treatment with a particular agent. In this review, we discuss the role of molecular markers in choosing appropriate treatment for the individual patient, along with the use of measuring the depth of response to a particular agent to assist decisions on whether to continue therapy in colorectal cancer. © 2014 Wiley Publishing Asia Pty Ltd.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "Asia Pacific Journal of Clinical Oncology" - Vol. 10, no. SUPPL.1, p. 2-10 (2014)
Peer reviewed yes
Publisher Wiley-Blackwell Publishing Ltd.
e-issn 1743-7563
issn 1743-7555
Publication status Publié
Affiliations UCL - (SLuc) Service d'hépato-gastro-entérologie
UCL - SSS/IREC - Institut de recherche expérimentale et clinique
Links
  1. Benedix Frank, Kube Rainer, Meyer Frank, Schmidt Uwe, Gastinger Ingo, Lippert Hans, Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival : , 10.1007/dcr.0b013e3181c703a4
  2. Meguid Robert A., Slidell Mark B., Wolfgang Christopher L., Chang David C., Ahuja Nita, Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?, 10.1245/s10434-008-0015-y
  3. Markowitz Sanford D., Bertagnolli Monica M., Molecular Basis of Colorectal Cancer, 10.1056/nejmra0804588
  4. Budinska Eva, Popovici Vlad, Tejpar Sabine, D'Ario Giovanni, Lapique Nicolas, Sikora Katarzyna Otylia, Di Narzo Antonio Fabio, Yan Pu, Hodgson John Graeme, Weinrich Scott, Bosman Fred, Roth Arnaud, Delorenzi Mauro, Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer : Gene expression heterogeneity in colorectal cancer, 10.1002/path.4212
  5. Cunningham David, Humblet Yves, Siena Salvatore, Khayat David, Bleiberg Harry, Santoro Armando, Bets Danny, Mueser Matthias, Harstrick Andreas, Verslype Chris, Chau Ian, Van Cutsem Eric, Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, 10.1056/nejmoa033025
  6. Saltz Leonard B., Meropol Neal J., Loehrer Patrick J., Needle Michael N., Kopit Justin, Mayer Robert J., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, 10.1200/jco.2004.10.182
  7. Lièvre Astrid, Bachet Jean-Baptiste, Le Corre Delphine, Boige Valérie, Landi Bruno, Emile Jean-François, Côté Jean-François, Tomasic Gorana, Penna Christophe, Ducreux Michel, Rougier Philippe, Penault-Llorca Frédérique, Laurent-Puig Pierre, KRASMutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, 10.1158/0008-5472.can-06-0191
  8. Van Cutsem Eric, Köhne Claus-Henning, Hitre Erika, Zaluski Jerzy, Chang Chien Chung-Rong, Makhson Anatoly, D'Haens Geert, Pintér Tamás, Lim Robert, Bodoky György, Roh Jae Kyung, Folprecht Gunnar, Ruff Paul, Stroh Christopher, Tejpar Sabine, Schlichting Michael, Nippgen Johannes, Rougier Philippe, Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, 10.1056/nejmoa0805019
  9. Karapetis Christos S., Khambata-Ford Shirin, Jonker Derek J., O'Callaghan Chris J., Tu Dongsheng, Tebbutt Niall C., Simes R. John, Chalchal Haji, Shapiro Jeremy D., Robitaille Sonia, Price Timothy J., Shepherd Lois, Au Heather-Jane, Langer Christiane, Moore Malcolm J., Zalcberg John R., K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer, 10.1056/nejmoa0804385
  10. Jonker Derek J., O'Callaghan Chris J., Karapetis Christos S., Zalcberg John R., Tu Dongsheng, Au Heather-Jane, Berry Scott R., Krahn Marianne, Price Timothy, Simes R. John, Tebbutt Niall C., van Hazel Guy, Wierzbicki Rafal, Langer Christiane, Moore Malcolm J., Cetuximab for the Treatment of Colorectal Cancer, 10.1056/nejmoa071834
  11. Amado Rafael G., Wolf Michael, Peeters Marc, Van Cutsem Eric, Siena Salvatore, Freeman Daniel J., Juan Todd, Sikorski Robert, Suggs Sid, Radinsky Robert, Patterson Scott D., Chang David D., Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, 10.1200/jco.2007.14.7116
  12. De Roock Wendy, Claes Bart, Bernasconi David, De Schutter Jef, Biesmans Bart, Fountzilas George, Kalogeras Konstantine T, Kotoula Vassiliki, Papamichael Demetris, Laurent-Puig Pierre, Penault-Llorca Frédérique, Rougier Philippe, Vincenzi Bruno, Santini Daniele, Tonini Giuseppe, Cappuzzo Federico, Frattini Milo, Molinari Francesca, Saletti Piercarlo, De Dosso Sara, Martini Miriam, Bardelli Alberto, Siena Salvatore, Sartore-Bianchi Andrea, Tabernero Josep, Macarulla Teresa, Di Fiore Frédéric, Gangloff Alice Oden, Ciardiello Fortunato, Pfeiffer Per, Qvortrup Camilla, Hansen Tine Plato, Van Cutsem Eric, Piessevaux Hubert, Lambrechts Diether, Delorenzi Mauro, Tejpar Sabine, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, 10.1016/s1470-2045(10)70130-3
  13. Tejpar Sabine, Celik Ilhan, Schlichting Michael, Sartorius Ute, Bokemeyer Carsten, Van Cutsem Eric, Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab, 10.1200/jco.2012.42.2592
  14. Baker J B, Dutta D, Watson D, Maddala T, Munneke B M, Shak S, Rowinsky E K, Xu L-A, Harbison C T, Clark E A, Mauro D J, Khambata-Ford S, Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer, 10.1038/sj.bjc.6606054
  15. Pentheroudakis George, Kotoula Vassiliki, De Roock Wendy, Kouvatseas George, Papakostas Pavlos, Makatsoris Thomas, Papamichael Demetris, Xanthakis Ioannis, Sgouros Joseph, Televantou Despina, Kafiri Georgia, Tsamandas Athanassios C, Razis Evangelia, Galani Eleni, Bafaloukos Dimitrios, Efstratiou Ioannis, Bompolaki Iliada, Pectasides Dimitrios, Pavlidis Nicholas, Tejpar Sabine, Fountzilas George, Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes, 10.1186/1471-2407-13-49
  16. Roock Wendy De, Vriendt Veerle De, Normanno Nicola, Ciardiello Fortunato, Tejpar Sabine, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, 10.1016/s1470-2045(10)70209-6
  17. Yang Zu-Yao, Wu Xin-Yin, Huang Ya-Fang, Di Meng-Yang, Zheng Da-Yong, Chen Jin-Zhang, Ding Hong, Mao Chen, Tang Jin-Ling, Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis : Biomarkers for Anti-EGFR Treatment of mCRC, 10.1002/ijc.28153
  18. Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras K T, Mazzucchelli L, Frattini M, Cappuzzo F, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients, 10.1038/bjc.2013.4
  19. Islam Rezwan, Chyou Po-Huang, Burmester James K, Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer, 10.7150/jca.6083
  20. Nishino Mizuki, Jagannathan Jyothi P., Krajewski Katherine M., O’Regan Kevin, Hatabu Hiroto, Shapiro Geoffrey, Ramaiya Nikhil H., Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST, 10.2214/ajr.11.7483
  21. Laubender, ASCO Meeting Abstracts, 30, 635 (2012)
  22. Mansmann, ASCO Meeting Abstracts, 31, 427 (2013)
  23. Suzuki C., Blomqvist L., Sundin A., Jacobsson H., Byström P., Berglund Å., Nygren P., Glimelius B., The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy, 10.1093/annonc/mdr350
  24. Piessevaux H., Buyse M., De Roock W., Prenen H., Schlichting M., Van Cutsem E., Tejpar S., Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial), 10.1093/annonc/mdp011
  25. Stintzing Sebastian, Kapaun Christine, Laubender Rüdiger Paul, Jung Andreas, Neumann Jens, Modest Dominik Paul, Giessen Clemens, Moosmann Nicolas, Wollenberg Andreas, Kirchner Thomas, Heinemann Volker, Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu, 10.1002/ijc.27654
  26. Van Cutsem Eric, Köhne Claus-Henning, Láng István, Folprecht Gunnar, Nowacki Marek P., Cascinu Stefano, Shchepotin Igor, Maurel Joan, Cunningham David, Tejpar Sabine, Schlichting Michael, Zubel Angela, Celik Ilhan, Rougier Philippe, Ciardiello Fortunato, Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status, 10.1200/jco.2010.33.5091
  27. Bokemeyer C., Bondarenko I., Hartmann J. T., de Braud F., Schuch G., Zubel A., Celik I., Schlichting M., Koralewski P., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, 10.1093/annonc/mdq632
  28. Maughan Timothy S, Adams Richard A, Smith Christopher G, Meade Angela M, Seymour Matthew T, Wilson Richard H, Idziaszczyk Shelley, Harris Rebecca, Fisher David, Kenny Sarah L, Kay Edward, Mitchell Jenna K, Madi Ayman, Jasani Bharat, James Michelle D, Bridgewater John, Kennedy M John, Claes Bart, Lambrechts Diether, Kaplan Richard, Cheadle Jeremy P, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, 10.1016/s0140-6736(11)60613-2
  29. Mansmann, ASCO Meeting Abstracts, 30, 580 (2012)
  30. Piessevaux, ASCO Meeting Abstracts, 29, 3572 (2011)
  31. Misale, Nature, 486, 532 (2012)
  32. Diaz, Nature, 486, 537 (2012)
  33. Basik Mark, Aguilar-Mahecha Adriana, Rousseau Caroline, Diaz Zuanel, Tejpar Sabine, Spatz Alan, Greenwood Celia M. T., Batist Gerald, Biopsies: next-generation biospecimens for tailoring therapy, 10.1038/nrclinonc.2013.101
  34. Wilson Timothy R., Fridlyand Jane, Yan Yibing, Penuel Elicia, Burton Luciana, Chan Emily, Peng Jing, Lin Eva, Wang Yulei, Sosman Jeff, Ribas Antoni, Li Jiang, Moffat John, Sutherlin Daniel P., Koeppen Hartmut, Merchant Mark, Neve Richard, Settleman Jeff, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, 10.1038/nature11249
  35. Heinemann, ASCO Meeting Abstracts, 31, LBA3506 (2013)
  36. Mansmann, ASCO Meeting Abstracts, 31, 3630 (2013)
  37. Clinicaltrials.gov Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2) http://www.clinicaltrials.gov/ct2/show/NCT01640444?term=bevacizumab+cetuximab&rank=1
  38. Mansmann, ASCO Meeting Abstracts, 31, 427 (2013)
Bibliographic reference Tejpar, Sabine ; Piessevaux, Hubert. Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: A future opportunity?. In: Asia Pacific Journal of Clinical Oncology, Vol. 10, no. SUPPL.1, p. 2-10 (2014)
Permanent URL http://hdl.handle.net/2078.1/160489